{"slug":"rcc","tag":"rcc","variants":["rcc"],"description":"No description yet","count":5,"kinds":{"person":5},"related":[{"slug":"trialist","tag":"trialist","shared":2},{"slug":"guidelines","tag":"guidelines","shared":1},{"slug":"hif2a","tag":"hif2a","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1},{"slug":"microbiome","tag":"microbiome","shared":1},{"slug":"surgery","tag":"surgery","shared":1},{"slug":"swog","tag":"swog","shared":1}],"records":[{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","route":"/people/robert-motzer/","tldr":"The kidney cancer trialist behind sunitinib, CheckMate 214 and CLEAR, three shifts in first-line standard of care."},{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/","tldr":"Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer."},{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","route":"/people/laurence-albiges/","tldr":"French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials."},{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","route":"/people/sumanta-pal/","tldr":"Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy."},{"id":"arnaud-mejean","kind":"person","name":"Arnaud Méjean","route":"/people/arnaud-mejean/","tldr":"Surgeon who led CARMENA, the trial that showed most metastatic kidney cancer patients do not benefit from removing the kidney."}]}